Skip to main content

Month: August 2025

Nykredit Realkredit A/S H1 Interim Reports 2025

 To        Nasdaq Copenhagen A/Sand the press13 August 2025Nykredit today announces its H1 Interim Reports 2025 of: Nykredit A/S, CVR no 12 71 92 48Nykredit Realkredit A/S, CVR no 12 71 92 80Nykredit Bank A/S, CVR no 10 51 96 08Totalkredit A/S, CVR no 21 83 22 78 As a result of the acquisition of Spar Nord completed on 28 May 2025, the Nykredit Group’s H1 Interim Report 2025 has been changed. Spar Nord has been included in the Nykredit Group’s H1 Interim Financial Statements for the period from 28 May to 30 June 2025. The Nykredit Group’s full-year profit guidance includes Spar Nord’s financial results for the period from 28 May to 31 December 2025. Michael Rasmussen, Group Chief Executive, comments on the Nykredit Group’s H1 Interim Financial Statements and guidance upgrade:We are pleased to...

Continue reading

Financial results for H1 2025

Company announcement no. 25 Profit after tax of DKK 707 million and return on equity of 10.0% In terms of financial performance, the first half of 2025 delivered a profit after tax of DKK 707 million, corresponding to a return on equity after tax of 10.0%. The result is affected by the falling level of interest rates, with a lower return on the Bank’s substantial excess liquidity contributing to a reduction in net interest income. Moreover, there were total restructuring provisions of DKK 350 million and one-off costs for advisory services in connection with Nykredit’s acquisition of Spar Nord. Against this background, the Bank realized a profit before impairment charges which was DKK 657 million lower than in the same period of last year. When compiling the profit for the period excluding items regarding Nykredit’s takeover, Spar...

Continue reading

Sp Mortgage Bank Plc’s and Savings Banks Group’s Half year financial report for January – June 2025 has been published

Sp Mortgage Bank Plc  Stock Exchange Release  13 August 2025 at 8:00 am (CET +1)   Sp Mortgage Bank Plc’s and Savings Banks Group’s Half year financial report for January – June 2025 and Pillar III Disclosure Report 30 June 2025 has been published.    The materials are available at www.saastopankki.fi.   SP MORTGAGE BANK PLC   Additional information:   Kai Koskela, Managing Director Savings Banks Union Coop kai.koskela@saastopankki.fi  +358 40 549 0430  Tero Kangas, Managing Director   Sp Mortgage Bank Plc  tero.kangas@saastopankki.fi  +358 50 420 1022  Sp Mortgage Bank Plc is part of the Savings Banks Group and the Savings Banks Amalgamation. The role of Sp Mortgage Bank is, together with Central Bank of Savings Banks Finland Plc, to be responsible for obtaining funding for the Savings Banks Group from money and capital...

Continue reading

Central Bank of Savings Banks Finland Plc’s and Savings Banks Group’s Half year financial report for January – June 2025 has been published

Central Bank of Savings Banks Finland Plc  Stock Exchange Release  13 August 2025 at 8:00 am (CET +1)   Central Bank of Savings Banks Finland Plc’s and Savings Banks Group’s Half year financial report for January-June 2025 and Pillar III Disclosure Report 30 June 2025 has been published.    The materials are available at www.saastopankki.fi.   CENTRAL BANK OF SAVINGS BANKS FINLAND PLC   Additional information:   Kai Koskela, Managing Director   Savings Banks Union Coop  kai.koskela@saastopankki.fi  +358 40 549 0430    Mervi Luurila, Managing Director  Central Bank of Savings Banks Finland Plc  mervi.luurila@saastopankki.fi  +358 50 341 1196   Central Bank of Savings Banks Finland Plc belongs to the Savings Banks Amalgamation and Savings Banks Group and acts as Group’s central credit institution. Central Bank of Savings...

Continue reading

Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye

Pratteln, Switzerland, 13 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion of AGAMREE® (vamorolone) in Türkiye for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Supply and sales by GEN are expected to start in the first half of 2026, initially on a named patient basis, followed by commercial sales. Santhera has received a small upfront payment and, as per previous agreements, will receive an ongoing percentage of net sales. Dario Eklund, Chief Executive Officer of Santhera, said: “As leaders in the Turkish specialty pharmaceuticals market, GEN were a natural choice for Santhera as we looked for a high-quality distribution partner. We look forward to...

Continue reading

Lerøy Seafood Group ASA: Invitation to presentation of results for Q2 and first half 2025

Lerøy Seafood Group ASA will present its results for Q2 2025 on 20 August 2025 at Scandic Flesland Airport hotel in Bergen at 08:45 CET during the event “Vestland på Børs”. The presentation will be held in Norwegian followed by a Q&A session. You may alternatively follow the Norwegian presentation and submit questions through a live broadcast available on https://www.leroyseafood.com/no/investor/. The quarterly report and presentation will be published at 06:30 CET. A recording of the presentation in English will be available from 13:15 CET on https://www.leroyseafood.com/no/investor/. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.  

Continue reading

Comstock Prices $30 Million Upsized and Oversubscribed Public Offering of Common Stock

With the elimination of all outstanding debt and approximately $45 million in expected cash on hand, Comstock is positioned to fully fund the commercialization of its first industry-scale Comstock Metals facility and advance key development initiatives Offering includes participation from fundamental institutional investors, including a long-only mutual fund, a leading alternative asset manager, several preeminent global investment managers, and existing investorsVIRGINIA CITY, Nev., Aug. 12, 2025 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”), today announced that it has priced its previously announced underwritten public offering of 13,333,334 shares of its common stock at a price to the public of $2.25 per share (the “Offering”). All of the shares of common stock in the offering are to be sold...

Continue reading

Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Compass are expected to be approximately $120 million, before...

Continue reading

SPX Announces Pricing of Public Offering of Common Stock

CHARLOTTE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) — SPX Technologies, Inc. (NYSE:SPXC) (“SPX”) announced today the pricing of an underwritten public offering of 2,659,575 shares of its common stock at a public offering price of $188.00 per share. The gross proceeds to SPX from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $500.0 million. All shares in the offering are to be sold by SPX. In addition, SPX has granted the underwriters a 30-day option to purchase up to an additional 398,936 shares of its common stock offered in the public offering. The offering is expected to close on or about August 14, 2025, subject to customary closing conditions. BofA Securities, J.P. Morgan, and Wells Fargo Securities are acting as joint book-running managers for the...

Continue reading

Discovery of Copper Mineralization in 400 Metre Step-Out Drill Hole, Four Kilometres North of the Mount Polley Mill

VANCOUVER, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) — Imperial Metals Corporation (“Imperial” or the “Company”) (TSX:III) reports that an exploration drill hole, drilling a blind target through clastic cover rocks, intercepted a hydrothermal breccia hosting significant visual native copper at the unconformity with the Mount Polley Intrusive Complex (MPIC). Two intercepts in diamond drill hole FP-25-01 of 7.0 metres grading 0.70% copper and 0.27 g/t gold starting at 383.0 metres, and 20.0 metres grading 0.25% copper and 0.96 g/t gold starting at 417.5 metres, mark the discovery of significant mineralization in a major step-out. The drill hole was collared 4.15 kilometres north of the operating Mount Polley mill (see Figure 1).Hole ID From (m) To (m) Width (m) Copper (%) Gold (g/t) Copper Oxide Ratio(% )*FP-25-01 383.0 390.0 7.0 0.70 0.27 9%  and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.